TY - JOUR
T1 - Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - Conference Participants
AU - Swanepoel, Charles R.
AU - Atta, Mohamed G.
AU - D'Agati, Vivette D.
AU - Estrella, Michelle M.
AU - Fogo, Agnes B.
AU - Naicker, Saraladevi
AU - Post, Frank A.
AU - Wearne, Nicola
AU - Winkler, Cheryl A.
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Wyatt, Christina M.
AU - Abu-Alfa, Ali
AU - Adu, Dwomoa
AU - Agodoa, Lawrence Y.
AU - Alpers, Charles E.
AU - Arogundade, Fatiu A.
AU - Ashuntantang, Gloria
AU - Bagnis, Corinne I.
AU - Bhimma, Raj
AU - Brocheriou, Isabelle
AU - Cohen, Arthur H.
AU - Cohen, Karen
AU - Cook, H. Terence
AU - de Seigneux, Sophie
AU - Fabian, June
AU - Finkelstein, Fredric O.
AU - Haas, Mark
AU - Hamzah, Lisa
AU - Hendry, Bruce M.
AU - Imonje, Valentine
AU - Jennette, J. Charles
AU - Kimmel, Paul L.
AU - Klotman, Mary E.
AU - Klotman, Paul E.
AU - Larsen, Chris P.
AU - McCulloch, Mignon I.
AU - Mosiane, Pulane
AU - Nast, Cynthia C.
AU - Okpechi, Ikechi G.
AU - Ray, Patricio E.
AU - Rosenberg, Avi Z.
AU - Ross, Michael J.
AU - Ryom, Lene
AU - Truong, Luan
AU - Ulasi, Ifeoma
AU - Vogt, Liffert
AU - Zeier, Martin
PY - 2018
Y1 - 2018
N2 - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
AB - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041607294&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29398134
U2 - https://doi.org/10.1016/j.kint.2017.11.007
DO - https://doi.org/10.1016/j.kint.2017.11.007
M3 - Article
C2 - 29398134
SN - 0085-2538
VL - 93
SP - 753
EP - 760
JO - Kidney International
JF - Kidney International
IS - 3
ER -